Endocannabinoid system targeted therapeutics market is projected to be over USD 5 billion by 2030


Most cannabinoid-based drug candidates are being developed to target the CB1 and CB2 receptors.

.

Over time, extensive RD on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids. Over 175 drugs targeting the endocannabinoid system are currently under development.

 

 

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:

  • Target Disease Indication
  • Cancer
  • Genetic Disorders
  • Neurological Indications
  • Others

 

  • Route of Administration
  • Oral
  • Inhalation

 

  • Key Geographies
  • North America
  • Europe

Asia-Pacific and the Rest of the World

 

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features the following companies, which we identified to be key players in this domain:

  • GW Pharmaceuticals
  • Corbus Pharmaceuticals
  • Tilray
  • Tetra Bio-Pharma
  • Botanix Pharmaceuticals
  • Kalytera Therapeutics
  • Therapix Biosciences
  • Echo Pharmaceuticals
  • Avicanna
  • GB Sciences

 

Table of Contents

 

  1. PREFACE

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

 

  1. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS

 

  1. COMPANY PROFILES

 

  1. ACADEMIC GRANTS ANALYSIS

 

  1. PARTNERSHIPS AND COLLABORATIONS

 

  1. MERGERS AND ACQUISITIONS

 

  1. DRUG DEVELOPMENT STRATEGY ANALYSIS
  2. MARKET FORECAST AND OPPORTUNITY ANALYSIS

 

  1. CONCLUDING REMARKS

 

  1. EXECUTIVE INSIGHTS

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Comments